Glaukos Corporation GKOS
Glaukos Corporation (NYSE: GKOS) is an ophthalmology drug developer. Its lead program, iDose TR (travoprost intracameral implant), is in Phase 3 for Open-angle glaucoma / ocular hypertension (IOP reduction).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| iDose TR | Open-angle glaucoma / ocular hypertension | device-combination | Approved |
| Epioxa (iLink epi-on) | Keratoconus | device-combination | Approved |
| Photrexa (iLink epi-off) | Keratoconus | device-combination | Approved |
| Mitosol (mitomycin-C) | Adjunct in glaucoma filtration surgery | small molecule | Approved |
| iDose TRIO | Glaucoma | device-combination | Phase 3 |
| iDose TREX (second-generation extended release) | Glaucoma | device-combination | Phase 2 |
| iLink third generation | Corneal disorders | device-combination | Phase 2 |
| iLution Blepharitis | Demodex blepharitis | small molecule | Phase 2 |
| GLK-401 (IVT multi-kinase inhibitor) | Wet AMD, DME, RVO | small molecule | Phase 2 |
| iVeena | Not stated in extract | unclear | Phase 1 |
| iStent infinite PMA pivotal trial | Mild-to-moderate glaucoma | device-combination | NA_NON_THERAPEUTIC |
| PRESERFLO MicroShunt (US IDE / Phase 3) | Glaucoma | device-combination | NA_NON_THERAPEUTIC |
Recent results and decisions
- Jul 29, 2026completed enrollment Glaukos completed patient enrollment in the US 510(k) pivotal study of PRESERFLO MicroShunt in July 2026.
Completed patient enrollment in 510(k) pivotal study for PRESERFLO™ MicroShunt (July 2026)
Filing - Jul 29, 2026completed enrollment Glaukos completed enrollment in the Phase 2 trial of iLution Blepharitis in 2Q 2026.
Completed enrollment in Phase 2 clinical trial for iLution™ Blepharitis (2Q 2026)
Filing - May 4, 2026completed enrollment Glaukos completed patient enrollment in the Phase 3b study of iDose TRIO.
IND amendment filed December 2025; completed patient enrollment in Phase 3b study
Filing
6 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 ophthalmology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.